Midalozam

Phase 3Small molecule

Idorsia Pharmaceuticals Ltd.

Midalozam is one of 30 small molecule programs targeting Cataract. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

CataractPhase 3

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 2

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 3

Idose TR

GGlaukos Corporation

Phase 3

1 4

OCS-01

QQuan Dong Nguyen

Phase 3

1 5

Midalozam

Idorsia Pharmaceuticals Ltd.

Phase 3

2 6

XG-102

XXigen SA

Phase 3

2 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Kenalog

BBassett Healthcare

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Cataract

NCT07347886

Clinical

Trials by Indication[1]

Cataract2 trials

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Recruiting·MMelt Pharmaceuticals·Phase 3·NCT06383273·528 enrolled

Clinical Outcomes of Sedation in Cataract Surgery Performed Under Topical Anesthesia

Not yet recruiting·IIstanbul University - Cerrahpasa·N/A·NCT07347886·120 enrolled

Midazolam1 trial

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT02841761·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Midalozam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Midalozam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Midalozam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Idorsia Pharmaceuticals Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Idorsia Pharmaceuticals Ltd.

Midalozam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cataract2 trials

Midazolam1 trial

References

Drug Info

Quick Facts

Related News